National Antimicrobial Resistance Monitoring System using Retail Meat for Louisiana

NARMS合作协议计划，以提高和加强抗生素 零售食物样本的抗药性监测 机构资助机会编号：PA-20-124 路易斯安那 7/1/2020-6/30/2021 摘要 该项目将涉及采购，加工， 每月化验48个肉类及海鲜样本。ID Epi将识别，收集和 在FDA和NARMS的时间限制内处理样品。三个人从ID Epi致力于及时收集和提交。 增加和改进对特定于以下的抗菌素耐药性数据的分析： 路易斯安那州，将审查的趋势和关系，用来更好地告知 机构和公众，并进行研究，以制定缓解和/或预防政策。 这些活动将表明国家卫生部门在以下方面的重要性： 保护和改善公众健康。 增加额外的目标微生物和改进实验室技术， 例如将全基因组测序扩展到其他生物， 提供更高质量的信息，并提高查明相关病例或疫情的能力， 过去，现在，未来。该计划将促进与FDA的协调 和其他机构对疫情的调查。该计划还将提供质量 FDA NARMS计划还可以使用零售肉类和海鲜监测数据， 其他国家的数据。这种高质量数据的增加可以用来影响政策 关于抗菌药物的使用、耐药性和耐药性趋势。

NARMS Cooperative Agreement Program to Enhance and Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens Agency Funding Opportunity Number: PA-20-124 Louisiana 7/1/2020-6/30/2021 Abstract This project will involve the successful completion of the purchasing, processing, and testing of 48 meat and seafood samples per month. ID Epi will identify, collect and process samples within the FDA's and NARMS time constraints. Three persons from ID Epi are dedicated to timely collections and submissions. The increase in and improved analysis of antimicrobial resistance data specific to Louisiana, will be scrutinized for trends and relationships, used to better inform the agency and the public, and studied to develop policies for mitigation and/or prevention. These activities will demonstrate the importance of the state health department in protecting and improving the public's health. The addition of additional target organisms and improvement of laboratory techniques, such as the extension of whole genome sequencing to additional organisms, will permit higher quality information and increased ability to identify related cases or outbreaks in the past, at present, and in the future. The program will facilitate coordination with FDA and other agencies in investigations of outbreaks. The program will also provide quality retail meat and seafood surveillance data the FDA NARMS program can use in addition to other states' data. This increase in quality data can be used to influence policy regarding antimicrobial use, resistance and trends in resistance.